Sun Pharm Inds Inc Drug Patent Portfolio

Sun Pharm Inds Inc owns 5 orange book drugs protected by 22 US patents with Sezaby having the least patent protection, holding only 1 patent. And Levulan with maximum patent protection, holding 11 patents. Given below is the list of Sun Pharm Inds Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11857683 Stabilization of phenobarbital sodium for injection 07 Apr, 2042
Active
US11919907 Deuterated JAK inhibitor and uses thereof 21 May, 2041
Active
US10357567 Methods for photodynamic therapy 12 Jan, 2038
Active
US11077192 Methods for photodynamic therapy 12 Jan, 2038
Active
US11135293 Methods for photodynamic therapy 12 Jan, 2038
Active
US11571478 Methods for photodynamic therapy 12 Jan, 2038
Active
US11690914 Methods for photodynamic therapy 12 Jan, 2038
Active
US10561659 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
Active
US12076323 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
Active
US10172802 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
Active
US9707182 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
Active
US7435427 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US8367102 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US8952064 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US9078925 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US9089534 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US7723910 Method of photodynamically diagnosing or treating a contoured surface 17 Jun, 2019 Expired
US6709446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light 01 May, 2018 Expired
US8216289 Illuminator for photodynamic therapy 01 May, 2018 Expired
US8758418 Illuminator for photodynamic therapy 01 May, 2018 Expired
US5954703 Method and apparatus for applying 5-aminolevulinic acid 31 Oct, 2017 Expired
US5079262 Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid 30 Sep, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Sun Pharm Inds Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 08 Feb, 2024 US8367102 (Litigated)
Patent eGrant Notification 02 Jan, 2024 US11857683
Patent Issue Date Used in PTA Calculation 02 Jan, 2024 US11857683
Email Notification 02 Jan, 2024 US11857683
Recordation of Patent eGrant 02 Jan, 2024 US11857683
Recordation of Patent Grant Mailed 02 Jan, 2024 US11857683
Mail Patent eGrant Notification 02 Jan, 2024 US11857683
Email Notification 14 Dec, 2023 US11857683
Issue Notification Mailed 13 Dec, 2023 US11857683
Dispatch to FDC 29 Nov, 2023 US11857683
Application Is Considered Ready for Issue 29 Nov, 2023 US11857683
Issue Fee Payment Verified 17 Nov, 2023 US11857683
Issue Fee Payment Received 17 Nov, 2023 US11857683
Response to Reasons for Allowance 17 Nov, 2023 US11857683
Mail Acknowledgement of Priority Papers-Pub 13 Oct, 2023 US11857683


Sun Pharm Inds Inc's Drug Patent Litigations

Sun Pharm Inds Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 22, 2018, against patent number US8216289. The petitioner Biofrontera Incorporated, challenged the validity of this patent, with DUSA Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Sun Pharm Inds Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10357567 October, 2021 Terminated
(24 Jan, 2022)
DUSA Pharmaceuticals, Inc. et al. Biofrontera Inc. et al.
US8216289 August, 2018 Terminated-Denied
(26 Feb, 2019)
DUSA Pharmaceuticals Inc. Biofrontera Incorporated


Sun Pharm Inds Inc's Family Patents

Sun Pharm Inds Inc drugs have patent protection in a total of 7 countries. It's US patent count contributes only to 35.0% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Sun Pharm Inds Inc Drug List

Given below is the complete list of Sun Pharm Inds Inc's drugs and the patents protecting them.


1. Absorica

Absorica is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7435427 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(3 years ago)
Expired
US8367102 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(3 years ago)
Expired
US8952064 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(3 years ago)
Expired
US9078925 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(3 years ago)
Expired
US9089534 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica's drug page


2. Leqselvi

Leqselvi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11919907 Deuterated JAK inhibitor and uses thereof 21 May, 2041
(16 years from now)
Active
US10561659 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
(12 years from now)
Active
US12076323 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqselvi's drug page


3. Levulan

Levulan is protected by 11 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10357567 Methods for photodynamic therapy 12 Jan, 2038
(13 years from now)
Active
US11077192 Methods for photodynamic therapy 12 Jan, 2038
(13 years from now)
Active
US11135293 Methods for photodynamic therapy 12 Jan, 2038
(13 years from now)
Active
US11571478 Methods for photodynamic therapy 12 Jan, 2038
(13 years from now)
Active
US11690914 Methods for photodynamic therapy 12 Jan, 2038
(13 years from now)
Active
US7723910 Method of photodynamically diagnosing or treating a contoured surface 17 Jun, 2019
(5 years ago)
Expired
US6709446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light 01 May, 2018
(6 years ago)
Expired
US8216289 Illuminator for photodynamic therapy 01 May, 2018
(6 years ago)
Expired
US8758418 Illuminator for photodynamic therapy 01 May, 2018
(6 years ago)
Expired
US5954703 Method and apparatus for applying 5-aminolevulinic acid 31 Oct, 2017
(7 years ago)
Expired
US5079262 Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid 30 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levulan's drug page


4. Ortikos

Ortikos is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10172802 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
(11 years from now)
Active
US9707182 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortikos's drug page


5. Sezaby

Sezaby is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11857683 Stabilization of phenobarbital sodium for injection 07 Apr, 2042
(17 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sezaby's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List